Subscribe
shutterstock_529874140_steven_frame
Steven Frame / Shutterstock.com
11 January 2021AmericasRory O'Neill

SCOTUS weighs future of assignor estoppel

The US Supreme Court will decide whether or not to maintain a legal doctrine which stops inventors who sell their patent rights from later claiming the patents are invalid.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Roche urges SCOTUS to cancel Illumina patent win
8 January 2021   Roche has asked the US Supreme Court to declare that methods of separating DNA are not patent-eligible.
Americas
GSK, Amgen want SCOTUS to protect genus claims
18 November 2020   Patent law experts and pharmaceutical companies have lent their support to Merck Sharp & Dohme in its effort to confirm the patent-eligibility of genus claims at the US Supreme Court.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

More on this story

Americas
Roche urges SCOTUS to cancel Illumina patent win
8 January 2021   Roche has asked the US Supreme Court to declare that methods of separating DNA are not patent-eligible.
Americas
GSK, Amgen want SCOTUS to protect genus claims
18 November 2020   Patent law experts and pharmaceutical companies have lent their support to Merck Sharp & Dohme in its effort to confirm the patent-eligibility of genus claims at the US Supreme Court.

More on this story

Americas
Roche urges SCOTUS to cancel Illumina patent win
8 January 2021   Roche has asked the US Supreme Court to declare that methods of separating DNA are not patent-eligible.
Americas
GSK, Amgen want SCOTUS to protect genus claims
18 November 2020   Patent law experts and pharmaceutical companies have lent their support to Merck Sharp & Dohme in its effort to confirm the patent-eligibility of genus claims at the US Supreme Court.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?